文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Understanding Treatment Tolerability in Older Adults With Cancer.

作者信息

Flannery Marie A, Culakova Eva, Canin Beverly E, Peppone Luke, Ramsdale Erika, Mohile Supriya G

机构信息

University of Rochester Medical Center, School of Nursing, Rochester, NY.

Department of Surgery, University of Rochester Medical Center, Rochester, NY.

出版信息

J Clin Oncol. 2021 Jul 1;39(19):2150-2163. doi: 10.1200/JCO.21.00195. Epub 2021 May 27.

DOI:10.1200/JCO.21.00195
PMID:34043433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8238902/
Abstract
摘要

相似文献

[1]
Understanding Treatment Tolerability in Older Adults With Cancer.

J Clin Oncol. 2021-7-1

[2]
Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.

Cancer Med. 2020-11

[3]
[Randomizations!].

Cancer Radiother. 1998-12

[4]
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient.

Oncology (Williston Park). 2019-11-14

[5]
Examining heterogeneity in phase II trial designs may improve success in phase III.

J Natl Cancer Inst. 2008-2-6

[6]
Sorafenib [corrected] in kidney cancer.

Ann Oncol. 2007-7

[7]
Tools for decision-making in older cancer patients. Role of the comprehensive geriatric assessment.

Anticancer Agents Med Chem. 2014-6

[8]
Treating older adults with cancer: geriatric perspectives.

Am Soc Clin Oncol Educ Book. 2015

[9]
The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials Conference.

Am J Clin Oncol. 1996-8

[10]
SOP 09: Statistical design and analysis.

Onkologie. 2003-10

引用本文的文献

[1]
Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.

J Transl Med. 2025-5-16

[2]
Symptoms, Symptom Profiles, and Healthcare Utilization in Patients with Hematologic Malignancies: A Retrospective Observational Cohort Study and Latent Class Analysis.

Curr Oncol. 2025-1-25

[3]
Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials.

J Natl Cancer Inst Monogr. 2025-3-1

[4]
Relationships between patient-reported and clinician-rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy.

Cancer. 2025-2-15

[5]
Global burden of cancer pattern in 2020 & prediction to 2040 among older adults.

Indian J Med Res. 2024-11

[6]
Effect of polypharmacy and potentially inappropriate medications on physical functional decline among older adults with advanced cancer receiving systemic treatment.

Support Care Cancer. 2024-9-19

[7]
"I have a doctor that handles all the other stuff." Perceptions of older adults with cancer about discussing aging-related conditions with their oncologists.

J Geriatr Oncol. 2025-1

[8]
Associations of tumor-related psychiatric symptoms and healthy behaviors with dynamic quality of life after hepatocellular carcinoma hepatectomy.

Support Care Cancer. 2024-8-14

[9]
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review.

Breast Cancer Res Treat. 2024-11

[10]
Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis.

Target Oncol. 2024-7

本文引用的文献

[1]
Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.

J Clin Oncol. 2021-2-20

[2]
Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

J Patient Rep Outcomes. 2020-12-10

[3]
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Clin Trials. 2021-2

[4]
Measuring functional status of older adults with cancer with patient and performance-based measures, a how-to guide: A young society of geriatric oncology and nursing and allied health initiative.

J Geriatr Oncol. 2021-4

[5]
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions.

CA Cancer J Clin. 2021-1

[6]
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.

J Geriatr Oncol. 2021-3

[7]
Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812).

J Geriatr Oncol. 2021-5

[8]
Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer.

J Geriatr Oncol. 2021-3

[9]
Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials.

J Natl Cancer Inst. 2021-5-4

[10]
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.

J Clin Oncol. 2020-10-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索